Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Onco Targets Ther · 2016 · PMC4706127 · PMID 26770060

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this regard, a subanalysis of the TRIBE study recently showed a trend for increased survival with FOLFOXIRI compared to FOLFIRI (irinotecan with fluorouracil and folinic acid) in BRAF-positive patients, this difference was not statistically significant possibly due to the low prevalence of BRAF-positive CRC. 54 Ongoing studies are evaluating BRAF inhibitors in combin

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.